Bladder and upper urinary tract cancers as first and second primary cancers. Issue 6 (11th June 2021)

• Record Type: Journal Article
• Authors: Zheng, Guoqiao; Sundquist, Kristina; Sundquist, Jan; Försti, Asta; Hemminki, Otto; Hemminki, Kari
• Is Part Of: Cancer reports. Volume 4:Issue 6(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-11
• Subjects: cancer etiology -- relative risk -- renal pelvic cancer -- second primary cancer -- ureter cancer -- urothelial cancer; Cancer -- Periodicals; 616.994005
• DOI: 10.1002/cnr2.1406
• Languages: English
• ISSNs: 2573-8348

Abstract

Abstract: Background: Previous population‐based studies on second primary cancers (SPCs) in urothelial cancers have focused on known risk factors in bladder cancer patients without data on other urothelial sites of the renal pelvis or ureter. Aims: To estimate sex‐specific risks for any SPCs after urothelial cancers, and in reverse order, for urothelial cancers as SPCs after any cancer. Such two‐way analysis may help interpret the results. Methods: We employed standardized incidence ratios (SIRs) to estimate bidirectional relative risks of subsequent cancer associated with urothelial cancers. Patient data were obtained from the Swedish Cancer Registry from years 1990 through 2015. Results: We identified 46 234 urinary bladder cancers (75% male), 940 ureteral cancers (60% male), and 2410 renal pelvic cancers (57% male). After male bladder cancer, SIRs significantly increased for 9 SPCs, most for ureteral (SIR 41.9) and renal pelvic (17.2) cancers. In the reversed order (bladder cancer as SPC), 10 individual FPCs were associated with an increased risk; highest associations were noted after renal pelvic (21.0) and ureteral (20.9) cancers. After female bladder cancer, SIRs of four SPCs were significantly increased, most for ureteral (87.8) and pelvic (35.7) cancers. Female bladder, ureteral, and pelvic cancers associated are with endometrial cancer. Conclusions: The risks of recurrent urothelial cancers were very high, and, at most sites, female risks were twice over the male risks. Risks persisted often to follow‐up periods of >5 years, motivating an extended patient follow‐up. Lynch syndrome‐related cancers were associated with particularly female urothelial cancers, calling for clinical vigilance.